Widerlöv E, Lewander T
Naunyn Schmiedebergs Arch Pharmacol. 1978 Sep;304(2):111-23. doi: 10.1007/BF00495547.
Male Sprague-Dawley rats were given 0.407 mmoles/kg of D,L-alpha-methyl-p-tyrosine methylester HCl (H44/68; alpha-MT) at eleven time-points between 0--24 h, or 8 doses between 0.013--1.628 mmoles/kg of the drug at 1 h before i.v. injection of 160 micronCi tyrosine-2,6-3H. The rats were killed 15 min after tyrosine-3H and brain alpha-MT, tyrosine and catecholamines (endogenous and labelled), and plasma alpha-MT and tyrosine (--3H) were chromatographically isolated before being assayed spectrophotofluorimetrically (endogenous) or by liquid scintillation methods (labelled compounds). A delayed penetration of alpha-MT from plasma into brain, different elimination rates of alpha-MT in plasma and brain, and decreasing brain/plasma drug concentration on increasing alpha-MT dosages, indicated, that alpha-MT in brain and plasma belong to different pharmacokinetic compartments. The endogenous levels of catecholamines in the time-response experiments, declined to a minimum 4 h after alpha-MT administration, where the dopamine level was 38% and the noradrenaline level 51% of the saline controls. Kinetic data of the catecholamine elimination is given. In the dose-response experiment the decrease in the endogenous catecholamine levels was dose-related up to 0.407 mmoles/kg of alpha-MT, with no further decline on higher doses. The maximal inhibition of brain catecholamine synthesis occurred within 30 min after alpha-MT administration and the inhibition correlated better with the brain than with plasma alpha-MT content. The inhibition was dose-related with a maximal synthesis inhibition of 95% for dopamine and 80% for noradrenaline at the highest dose of alpha-MT. The duration of synthesis inhibition and storage depletion were shorter for noradrenaline (12 h) than for dopamine (16 h). Further, the ED50 for synthesis inhibition of dopamine (0.057 mmoles/kg) was half of the ED50 for synthesis inhibition of noradrenaline (0.117 mmoles/kg). This might suggest different sensitivities towards alpha-MT or different availabilities of alpha-MT in the two neuron populations. At the three highest doses of alpha-MT there were signs of interference with the uptake process for tyrosine from plasma into the brain. This was indicated by increased plasma levels and decreased brain levels of tyrosine (--3H).
给雄性Sprague-Dawley大鼠在0至24小时内的11个时间点给予0.407毫摩尔/千克的D,L-α-甲基-对-酪氨酸甲酯盐酸盐(H44/68;α-MT),或者在静脉注射160微居里酪氨酸-2,6-³H前1小时给予0.013至1.628毫摩尔/千克该药物的8个剂量。在给予³H-酪氨酸15分钟后处死大鼠,在通过分光荧光法(内源性物质)或液体闪烁法(标记化合物)进行测定之前,通过色谱法分离脑α-MT、酪氨酸和儿茶酚胺(内源性和标记的)以及血浆α-MT和酪氨酸(-³H)。α-MT从血浆向脑的延迟渗透、血浆和脑中α-MT不同的消除速率以及随着α-MT剂量增加脑/血浆药物浓度降低,表明脑和血浆中的α-MT属于不同的药代动力学区室。在时间-反应实验中,儿茶酚胺的内源性水平在给予α-MT后4小时降至最低,此时多巴胺水平为生理盐水对照组的38%,去甲肾上腺素水平为51%。给出了儿茶酚胺消除的动力学数据。在剂量-反应实验中,内源性儿茶酚胺水平的降低在α-MT剂量达0.407毫摩尔/千克之前与剂量相关,更高剂量时不再进一步下降。脑儿茶酚胺合成的最大抑制在给予α-MT后30分钟内出现,并且该抑制与脑α-MT含量的相关性比与血浆α-MT含量的相关性更好。该抑制与剂量相关,在α-MT最高剂量时多巴胺合成的最大抑制为95%,去甲肾上腺素为80%。去甲肾上腺素(12小时)合成抑制和储存耗竭的持续时间比多巴胺(16小时)短。此外,多巴胺合成抑制的半数有效剂量(ED50)(0.057毫摩尔/千克)是去甲肾上腺素合成抑制的半数有效剂量(0.117毫摩尔/千克)的一半。这可能表明两个神经元群体对α-MT的敏感性不同或α-MT的可利用性不同。在α-MT的三个最高剂量时,有迹象表明从血浆向脑的酪氨酸摄取过程受到干扰。这表现为血浆中酪氨酸水平升高和脑中酪氨酸(-³H)水平降低。